2024
Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis
Wannan C, Nelson B, Addington J, Allott K, Anticevic A, Arango C, Baker J, Bearden C, Billah T, Bouix S, Broome M, Buccilli K, Cadenhead K, Calkins M, Cannon T, Cecci G, Chen E, Cho K, Choi J, Clark S, Coleman M, Conus P, Corcoran C, Cornblatt B, Diaz-Caneja C, Dwyer D, Ebdrup B, Ellman L, Fusar-Poli P, Galindo L, Gaspar P, Gerber C, Glenthøj L, Glynn R, Harms M, Horton L, Kahn R, Kambeitz J, Kambeitz-Ilankovic L, Kane J, Kapur T, Keshavan M, Kim S, Koutsouleris N, Kubicki M, Kwon J, Langbein K, Lewandowski K, Light G, Mamah D, Marcy P, Mathalon D, McGorry P, Mittal V, Nordentoft M, Nunez A, Pasternak O, Pearlson G, Perez J, Perkins D, Powers A, Roalf D, Sabb F, Schiffman J, Shah J, Smesny S, Spark J, Stone W, Strauss G, Tamayo Z, Torous J, Upthegrove R, Vangel M, Verma S, Wang J, Rossum I, Wolf D, Wolff P, Wood S, Yung A, Agurto C, Alvarez-Jimenez M, Amminger P, Armando M, Asgari-Targhi A, Cahill J, Carrión R, Castro E, Cetin-Karayumak S, Chakravarty M, Cho Y, Cotter D, D’Alfonso S, Ennis M, Fadnavis S, Fonteneau C, Gao C, Gupta T, Gur R, Gur R, Hamilton H, Hoftman G, Jacobs G, Jarcho J, Ji J, Kohler C, Lalousis P, Lavoie S, Lepage M, Liebenthal E, Mervis J, Murty V, Nicholas S, Ning L, Penzel N, Poldrack R, Polosecki P, Pratt D, Rabin R, Eichi H, Rathi Y, Reichenberg A, Reinen J, Rogers J, Ruiz-Yu B, Scott I, Seitz-Holland J, Srihari V, Srivastava A, Thompson A, Turetsky B, Walsh B, Whitford T, Wigman J, Yao B, Yuen H, Ahmed U, Byun A, Chung Y, Do K, Hendricks L, Huynh K, Jeffries C, Lane E, Langholm C, Lin E, Mantua V, Santorelli G, Ruparel K, Zoupou E, Adasme T, Addamo L, Adery L, Ali M, Auther A, Aversa S, Baek S, Bates K, Bathery A, Bayer J, Beedham R, Bilgrami Z, Birch S, Bonoldi I, Borders O, Borgatti R, Brown L, Bruna A, Carrington H, Castillo-Passi R, Chen J, Cheng N, Ching A, Clifford C, Colton B, Contreras P, Corral S, Damiani S, Done M, Estradé A, Etuka B, Formica M, Furlan R, Geljic M, Germano C, Getachew R, Goncalves M, Haidar A, Hartmann J, Jo A, John O, Kerins S, Kerr M, Kesselring I, Kim H, Kim N, Kinney K, Krcmar M, Kotler E, Lafanechere M, Lee C, Llerena J, Markiewicz C, Matnejl P, Maturana A, Mavambu A, Mayol-Troncoso R, McDonnell A, McGowan A, McLaughlin D, McIlhenny R, McQueen B, Mebrahtu Y, Mensi M, Hui C, Suen Y, Wong S, Morrell N, Omar M, Partridge A, Phassouliotis C, Pichiecchio A, Politi P, Porter C, Provenzani U, Prunier N, Raj J, Ray S, Rayner V, Reyes M, Reynolds K, Rush S, Salinas C, Shetty J, Snowball C, Tod S, Turra-Fariña G, Valle D, Veale S, Whitson S, Wickham A, Youn S, Zamorano F, Zavaglia E, Zinberg J, Woods S, Shenton M. Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis. Schizophrenia Bulletin 2024, 50: 496-512. PMID: 38451304, PMCID: PMC11059785, DOI: 10.1093/schbul/sbae011.Peer-Reviewed Original ResearchClinical high-risk individualsClinical high riskNational Institute of Mental HealthInstitute of Mental HealthAttenuated positive symptomsPersistent negative symptomsTransition to psychosisCHR statusHigh riskNegative symptomsPositive symptomsAnxiety symptomsPsychosocial functioningCognitive dataOutcomes of individualsDigital health technologiesDaily surveysPsychosisSCZPublic health needsMental healthNovel pharmacological interventionsSchizophreniaClinical outcomesHealth needs
2023
Sampling from different populations: Sociodemographic, clinical, and functional differences between samples of first episode psychosis individuals and clinical high-risk individuals who progressed to psychosis
Hagler M, Ferrara M, Yoviene Sykes L, Li F, Addington J, Bearden C, Cadenhead K, Cannon T, Cornblatt B, Perkins D, Mathalon D, Seidman L, Tsuang M, Walker E, Powers A, Allen A, Srihari V, Woods S. Sampling from different populations: Sociodemographic, clinical, and functional differences between samples of first episode psychosis individuals and clinical high-risk individuals who progressed to psychosis. Schizophrenia Research 2023, 255: 239-245. PMID: 37028205, PMCID: PMC10207144, DOI: 10.1016/j.schres.2023.03.047.Peer-Reviewed Original ResearchConceptsFirst-episode psychosis servicesClinical high riskClinical high-risk individualsEarly detectionFirst-episode psychosis individualsRecent psychiatric hospitalizationCourse of illnessHigh-risk individualsAttenuated positive symptomsCHR researchGeographic catchmentSyndromal psychosisPsychosis individualsPsychiatric hospitalizationEarly intervention effortsHigh riskPsychosis servicesPositive symptomsGlobal functioningClinical resourcesProtective factorsDifferent populationsFE participantsGeneralizability of findingsFES program
2022
Accelerated cortical thinning precedes and predicts conversion to psychosis: The NAPLS3 longitudinal study of youth at clinical high-risk
Collins M, Ji J, Chung Y, Lympus C, Afriyie-Agyemang Y, Addington J, Goodyear B, Bearden C, Cadenhead K, Mirzakhanian H, Tsuang M, Cornblatt B, Carrión R, Keshavan M, Stone W, Mathalon D, Perkins D, Walker E, Woods S, Powers A, Anticevic A, Cannon T. Accelerated cortical thinning precedes and predicts conversion to psychosis: The NAPLS3 longitudinal study of youth at clinical high-risk. Molecular Psychiatry 2022, 28: 1182-1189. PMID: 36434057, PMCID: PMC10005940, DOI: 10.1038/s41380-022-01870-7.Peer-Reviewed Original ResearchConceptsCHR-NCPercent thickness changeCortical thinningPsychosis onsetHealth controlsProgressive grey matter lossNorth American Prodrome Longitudinal StudyClinical high-risk individualsGray matter lossHigh-risk individualsLongitudinal studyGreater percent decreaseNovel treatment targetsParietal cortical regionsTargeted early interventionsCortical thicknessCortical areasMRI scansCHR individualsTreatment targetsEarly interventionCortical regionsLeft hemisphere regionsROC analysisHC participants